Capsaicin
Side effects
Options:
Show MedDRA Preferred Terms
|
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
|
1
|
2
|
|
Application site erythema
|
very common, 54% - 63%
|
|
x
|
x
|
|
Application site pain
|
very common, 21% - 42%
|
|
x
|
x
|
|
Application site pruritus
|
common, 4% - 6%
|
|
x
|
x
|
|
Application site vesicles
|
common
|
|
|
x
|
|
Application site papules
|
common, 3% - 6%
|
|
x
|
x
|
|
Application site oedema
|
common, 1% - 4%
|
|
x
|
x
|
|
Nasopharyngitis
|
2% - 4%
|
|
x
|
|
|
Nausea
|
uncommon, 2% - 5%
|
|
x
|
x
|
|
Sinusitis
|
1% - 3%
|
|
x
|
|
|
Vomiting
|
1% - 3%
|
|
x
|
|
|
Application site dryness
|
common, 1% - 2%
|
|
x
|
x
|
|
Application site swelling
|
common, 1% - 2%
|
|
x
|
x
|
|
Bronchitis
|
1% - 2%
|
|
x
|
|
|
Hypertension
|
uncommon, 1% - 2%
|
|
x
|
x
|
|
Cough
|
uncommon
|
|
x
|
x
|
|
Dysgeusia
|
uncommon
|
|
x
|
x
|
|
Herpes zoster
|
uncommon
|
|
|
x
|
|
Hypoaesthesia
|
uncommon
|
|
x
|
x
|
|
Pain in extremity
|
uncommon
|
|
|
x
|
|
Palpitations
|
uncommon
|
|
|
x
|
|
Pruritus
|
uncommon, 1% - 2%
|
|
x
|
x
|
|
Muscle spasms
|
uncommon
|
|
|
x
|
|
Tachycardia
|
uncommon
|
|
|
x
|
|
Burning sensation
|
uncommon
|
|
x
|
x
|
|
Oedema peripheral
|
uncommon
|
|
x
|
x
|
|
Application site reaction
|
uncommon
|
|
|
x
|
|
Eye irritation
|
uncommon
|
|
|
x
|
|
Blood pressure increased
|
uncommon
|
|
x
|
x
|
|
Application site irritation
|
uncommon
|
|
|
x
|
|
Application site rash
|
uncommon
|
|
x
|
x
|
|
Throat irritation
|
uncommon
|
|
x
|
x
|
|
Application site haematoma
|
uncommon
|
|
x
|
x
|
|
Application site paraesthesia
|
uncommon
|
|
x
|
x
|
|
Application site inflammation
|
uncommon
|
|
x
|
x
|
|
Application site hyperaesthesia
|
uncommon
|
|
x
|
x
|
|
Application site urticaria
|
uncommon
|
|
x
|
x
|
|
Infection
|
|
|
x
|
x
|
|
Connective tissue disorder
|
|
|
|
x
|
|
Dizziness
|
|
|
x
|
|
|
Eye disorder
|
|
|
|
x
|
|
Gastrointestinal disorder
|
|
|
x
|
x
|
|
Headache
|
|
|
x
|
|
|
Cardiac disorder
|
|
|
|
x
|
|
Hyperaesthesia
|
|
|
x
|
|
|
Mediastinal disorder
|
|
|
x
|
x
|
|
Nervous system disorder
|
|
|
x
|
x
|
|
Erythema
|
|
|
|
x
|
|
Angiopathy
|
|
|
x
|
x
|
|
HIV associated nephropathy
|
|
|
|
x
|
|
Peripheral sensory neuropathy
|
|
|
x
|
|
|
Eye pain
|
|
|
|
x
|
|
Unspecified disorder of skin and subcutaneous tissue
|
|
|
x
|
x
|
|
Skin odour abnormal
|
|
|
x
|
|
|
Application site anaesthesia
|
|
|
x
|
|
|
Burns second degree
|
|
|
|
x
|
|
Neuropathy
|
|
|
|
x
|
|
Infestation NOS
|
|
|
x
|
x
|
|
Application site warmth
|
|
|
x
|
|
|
Application site burn
|
|
|
|
x
|
|
Application site excoriation
|
|
|
x
|
|
|
Application site exfoliation
|
|
|
x
|
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
| Side effects: | 43 |
|---|
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 48 |
|---|
| Source: | EMA |
|---|
Color scheme:
standard – alternative
|
|
|
100%
|
|
|
|
75%
|
|
|
|
50%
|
|
|
|
10%
|
|
|
|
frequent (1% to 100%)
|
|
|
|
infrequent (0.1% to 1%)
|
|
|
|
rare (<0.1%)
|
|
|
|
postmarketing
|
|
|
|
0%
|
|
|
|
no frequency information
|
|
|
|
not found on label
|
